NCT05764486已完成不适用
A Study About the Operation Efficacy and the Early Stage Safety of Heavy Ion Beam Treatment System in Solid Tumor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Adverse event
研究概览
简要总结
The main purpose of this study is to investigate the safety of Hitachi's Heavy Ion Beam Therapy System HyBEAT for treating patients with solid tumor in Taipei Veterans General Hospital, including patients early-stage adverse reactions and the efficacy on tumors, as well as to assess the operation efficacy of the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be 20 years of age inclusive, male or female
- •Diagnosed with one of the following cancer: head and neck cancer, lung cancer, liver cancer, prostate cancer, osteosarcoma or bone and soft-tissue tumours
- •Having a lesion of less than 12cm
- •Having no metastasis at distant organ sites
- •Having a life expectancy of more than 12 weeks or longer
- •ECOG Performance Status (ECOG PS): 0, 1 or 2
- •Maintain the function of major organs and satisfy the following criteria: WBC≥3,000 / mm3 , Plt
- •≥75,000 / mm3 (assuming no serious bleeding tendency below 100,000), Hb≥9.5 g / dl
- •Able to maintain body position during irradiation
- •Based on his/her free will, agree to participate in the clinical study and sign and date the informed consent form after understanding the clinical study.
排除标准
- •Weigh more than or equal to 135kg
- •Subjects need chemotherapy or immunotherapy as concomitant treatment
- •Have received radiotherapy on the area planned to be irradiated
- •Have received local treatment that might potentially affect endpoint evaluation, 4 weeks prior to the screening process (for instance TACE etc.)
- •Have been treated with targeted therapy, chemotherapy or immunotherapy 4 weeks prior to the screening process
- •Participated in other clinical studies within 12 weeks before screening (studies using questionnaire are exemption)
- •Subjects contraindicated in using radiotherapy
- •Wearing electronic devices, for example implantable cardiac pacemakers, implantable defibrillators, cerebrospinal stimulators, artificial hearts and cochlear implants, where the function and activity may be affected by radiation
- •Have been diagnosed with another active, uncontrolled cancer
- •Subjects whose irradiated area has active or persistent infectious disease
- •Has autoimmune diseases or connective tissue diseases
- •Subjects with other serious complications
- •Pregnant or currently breastfeeding
- •Planning to give birth or unable to take contraception during the screening and treatment period, as well as within 52 weeks after receiving the last treatment, regardless of gender.
- •Subjects who are judged by the investigators as unsuitable
结局指标
主要结局
Adverse event
时间窗: up to 12 weeks
The adverse reactions and the severity of all subjects in the early stage will be evaluated.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Preliminary Evaluation of the Clinical Safety and Effectiveness of the Bionic Nerve ScaffoldPeripheral Nerve InjuriesNCT03780855Xijing Hospital10
已完成
1 期
Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic AneurysmsAbdominal Aortic AneurysmsNCT01328197Bolton Medical30
Unknown
不适用
Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver MetastasesNeoplasm MetastasisNCT01489787Centre Leon Berard38
已完成
不适用
Early-Phase Safety of Proton Therapy EquipmentMalignant GliomaHead and Neck Malignant TumorHepatocellular CarcinomaProstate CancerNCT02315989Chang Gung Memorial Hospital6
Unknown
2 期
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersThyroidMetastasisApatinibNCT04180007Nanjing First Hospital, Nanjing Medical University10